Lead Sponsor

Cooperative Research Centre for Biomedical Imaging Development

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Written informed consent obtained prior to any protocol-specific procedures
•Male and female patients with histologically confirmed melanoma
•At least one site of metastatic disease, as demonstrated on the pre-study 18F FDG PET/CT scan performed as part of routine clinical care
•Age \>/= 18 years
•Life expectancy \>/=3 months
•ECOG performance score of 0-2

•Pregnant or breastfeeding females
•Systemic anti-melanoma therapy within the 2 weeks prior to the pre-study 18F FDG PET/CT scan until after the 18F MEL050 PET/CT scan
•Patients whose clinical care may be compromised because of the delay resulting from performance of the 18F MEL050 PET/CT scan
•Patients whose only metastatic lesion is in the Central Nervous System
•Patients with urinary incontinence or patients who cannot comfortably hold their urine for more than 90 minutes
•Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study
•Patients unwilling or unable to comply with protocol and patients with a history of non compliance or inability to grant informed consent.

Related studies

NCT04771520 · Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, and more

NCT05588453 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, and more

NCT06500455 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

NCT07564570 · Metastatic Melanoma

NCT04693377 · Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, and more

Of 18F MEL050 Using PET/CT in Metastatic Melanoma